Clinical trials update from the European Society of Cardiology Heart Failure meeting: COMET, COMPANION, Tezosentan and SHAPE

This article continues a series of reports on recent research developments in the field of heart failure. Key presentations made at the European Society of Cardiology Heart Failure Update meeting, held in Strasbourg, France are described. The COMET study showed a 17% relative risk reduction in all‐c...

Full description

Saved in:
Bibliographic Details
Published in:European journal of heart failure 2003-08, Vol.5 (4), p.545-548
Main Authors: Coletta, Alison P., Clark, Andrew L., Seymour, Anne-Marie L., Cleland, John G.F.
Format: Article
Language:English
Subjects:
Adrenergic beta-Antagonists - therapeutic use
Carbazoles - therapeutic use
Cardiac Pacing, Artificial
Carvedilol
COMET
COMPANION
Defibrillators, Implantable
Endpoint Determination
Health Education
Heart Failure - drug therapy
Heart Failure - physiopathology
Heart Failure - therapy
Hemodynamics - drug effects
Humans
Metoprolol - therapeutic use
Propanolamines - therapeutic use
Pyridines - therapeutic use
Randomized Controlled Trials as Topic
SHAPE
Tetrazoles - therapeutic use
tezosentan
Treatment Outcome
Vasodilator Agents - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This article continues a series of reports on recent research developments in the field of heart failure. Key presentations made at the European Society of Cardiology Heart Failure Update meeting, held in Strasbourg, France are described. The COMET study showed a 17% relative risk reduction in all‐cause mortality with carvedilol compared with metoprolol tartrate. The COMPANION study, as previously reported, showed encouraging results for the use of cardiac resynchronisation and implantable defibrillator therapy in patients with heart failure, but further evidence is awaited. The results of a study on tezosentan suggest that lower doses of this endothelin antagonist may be clinically more effective with fewer adverse effects compared with higher doses. The SHAPE survey of heart failure awareness in Europe identified a need for further heart failure education amongst the public, patients, their carers and primary care physicians.
ISSN:1388-9842
1879-0844
DOI:10.1016/S1388-9842(03)00111-9